Fig. 1: The protein levels of CHES1 in TNBC and its clinical relevance to the prognosis of patients. | Cell Death Discovery

Fig. 1: The protein levels of CHES1 in TNBC and its clinical relevance to the prognosis of patients.

From: Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer

Fig. 1

A Western blot detected the protein levels of CHES1 in normal breast epithelial cell and breast cancer cells. B Representative images of IHC staining showed the expression pattern of CHES1 in subtypes of breast cancer tissues. C The quantified statistics for relative expression of CHES1 in subtypes of breast cancer tissues based on the IHC staining of tissue microarray. *p < 0.05, **p < 0.01. D Images of IHC staining showed the expression of CHES1 in TNBC tissues based on the Ki67 intensity. Quantification analysis was showed below. *p < 0.05. E Representative images of IHC staining assay showed the expression of CHES1 in TMA based on the lymphatic metastasis status. Quantification analysis were showed below. **p < 0.01. F, G. Kaplan–Meier curves of relapse-free survival times of total TNBC patients (n = 424) (F) and breast cancer patients with lymphatic metastasis (n = 154) (G) stratified by CHES1 expression levels. Data were obtained from the Kaplan–Meier Plotter dataset (http://kmplot.com/analysis/). CHES1 was analyzed with the best probe set (ID:222494_at) with gene chip dataset, the patient with TNBC was restricted by the expression status of ER, PR, and HER2 dectected by IHC or array analysis. Lymph node status was also considered as a restriction condition using the database provided subtype analysis tools. And standard for analysis was kept with default parameters. Statistical significance was determined by the log-rank test.

Back to article page